Opinion|Videos|April 11, 2025

Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

Listen
0:00 / 0:00

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Timecodes:

1:25- Rationale for high dose aflibercept

5:00- PULSAR trial for AMD

12:00- PHOTON trial for DME

16:21- Changing practice patterns

22:29- Faricimab and role of ang-2 inhibition

28:30 Impact of new therapies


Latest CME